Acute Myelocytic Leukemia Subtype Any | Acute Promyelocytic Leukemia Excluded | MYELODYSPLASTIC SYNDROME High risk | Blasts Bone marrow Percentage
Item
confirmed diagnosis of acute myeloid leukemia (aml), any subtype except acute promyelocytic leukemia (apl), by the world health organization (who) criteria, or high risk mds with blasts between 10 and 20% in the bone marrow.
boolean
C0023467 (UMLS CUI [1,1])
C0449560 (UMLS CUI [1,2])
C1552551 (UMLS CUI [1,3])
C0023487 (UMLS CUI [2,1])
C2828389 (UMLS CUI [2,2])
C3463824 (UMLS CUI [3,1])
C0332167 (UMLS CUI [3,2])
C1982687 (UMLS CUI [4,1])
C0439165 (UMLS CUI [4,2])
Chemotherapy Absent AML | hydroxyurea
Item
no prior aml chemotherapy except hydroxyurea.
boolean
C0392920 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0023467 (UMLS CUI [1,3])
C0020402 (UMLS CUI [2])
Leukemic Blast Count | Hydroxyurea Cytoreductive effect
Item
leukemic blast count <30x10^9/l at the start of therapy. prior cytoreduction with hydroxyurea (maximum 14 days) is permitted.
boolean
C2697913 (UMLS CUI [1])
C0020402 (UMLS CUI [2,1])
C0864494 (UMLS CUI [2,2])
Induction procedure intense Unfavorable | Risk Cytogenetic | Chromosome Deletion Complete | Chromosome Deletion Partial | Chromosome Aberrations | inv(3) Abnormality | Chromosome 11q23 Abnormality | secondary acute myeloid leukemia | Hematological Disease | Comorbidity Excludes Induction procedure | Induction procedure Refused
Item
participant is not a candidate for aggressive induction based on at least one of the following: adverse-risk cytogenetics (complete or partial deletion of 5 or 7, complex [>3] cytogenetic abnormalities, inv3, 11q23 abnormalities); secondary aml (antecedent hematologic disorder or therapy-related aml); comorbid medical illnesses precluding standard induction therapy; participant's refusal of standard induction therapy.
boolean
C0857127 (UMLS CUI [1,1])
C0522510 (UMLS CUI [1,2])
C3640815 (UMLS CUI [1,3])
C0035647 (UMLS CUI [2,1])
C0010802 (UMLS CUI [2,2])
C0008628 (UMLS CUI [3,1])
C0205197 (UMLS CUI [3,2])
C0008628 (UMLS CUI [4,1])
C0728938 (UMLS CUI [4,2])
C0008625 (UMLS CUI [5])
C3829508 (UMLS CUI [6,1])
C1704258 (UMLS CUI [6,2])
C0796367 (UMLS CUI [7,1])
C1704258 (UMLS CUI [7,2])
C0280449 (UMLS CUI [8])
C0018939 (UMLS CUI [9])
C0009488 (UMLS CUI [10,1])
C0332196 (UMLS CUI [10,2])
C0857127 (UMLS CUI [10,3])
C0857127 (UMLS CUI [11,1])
C1705116 (UMLS CUI [11,2])
MGMT expression low Western Blotting | beta-Actin | MGMT expression weak
Item
confirmed low mgmt expression (mgmt: beta-actin ≤0.2), as evaluated by western blot, or weak mgmt expression defined as > 0.2 and ≤2.5 if promoter is methylated, upon sponsor approval.
boolean
C0069197 (UMLS CUI [1,1])
C1171362 (UMLS CUI [1,2])
C0205251 (UMLS CUI [1,3])
C0005863 (UMLS CUI [1,4])
C0005186 (UMLS CUI [2])
C0069197 (UMLS CUI [3,1])
C1171362 (UMLS CUI [3,2])
C1762617 (UMLS CUI [3,3])
ECOG performance status
Item
eastern cooperative oncology group (ecog) performance status of 0, 1, or 2.
boolean
C1520224 (UMLS CUI [1])
Fertility Contraceptive methods
Item
use of medically approved contraception in fertile males and females.
boolean
C0015895 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
Childbearing Potential Urine pregnancy test negative | Childbearing Potential Serum pregnancy test negative
Item
negative urine or serum pregnancy test for women of childbearing potential (72 hours prior to baseline).
boolean
C3831118 (UMLS CUI [1,1])
C0430057 (UMLS CUI [1,2])
C3831118 (UMLS CUI [2,1])
C0430061 (UMLS CUI [2,2])
Serum bilirubin increased | Aspartate aminotransferase increased | Alanine aminotransferase increased
Item
serum bilirubin >2 times the upper limit of normal (uln), or serum aspartate aminotransferase/ alanine aminotransferase >5 times uln.
boolean
C0859062 (UMLS CUI [1])
C0151904 (UMLS CUI [2])
C0151905 (UMLS CUI [3])
Creatinine measurement, serum
Item
serum creatinine >200 umol/l.
boolean
C0201976 (UMLS CUI [1])
Malignant Neoplasms | Skin carcinoma Localized | Carcinoma in situ of uterine cervix
Item
history of other malignancies within 1 year prior to study entry, with the exception of localized nonmelanomatous skin cancer or cervical cancer in situ.
boolean
C0006826 (UMLS CUI [1])
C0699893 (UMLS CUI [2,1])
C0392752 (UMLS CUI [2,2])
C0851140 (UMLS CUI [3])
Communicable Disease Uncontrolled
Item
presence of active uncontrolled infection.
boolean
C0009450 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
HIV Infection
Item
known human immunodeficiency virus (hiv) infection.
boolean
C0019693 (UMLS CUI [1])
Medical condition Interferes with Protocol Evaluation | Medical condition Interferes with Oral medication Intake
Item
any medical condition that may interfere with protocol evaluation or oral medication intake.
boolean
C3843040 (UMLS CUI [1,1])
C0521102 (UMLS CUI [1,2])
C2348563 (UMLS CUI [1,3])
C1261322 (UMLS CUI [1,4])
C3843040 (UMLS CUI [2,1])
C0521102 (UMLS CUI [2,2])
C0175795 (UMLS CUI [2,3])
C1512806 (UMLS CUI [2,4])
Chemotherapy | hydroxyurea
Item
prior chemotherapy other than hydroxyurea.
boolean
C0392920 (UMLS CUI [1])
C0020402 (UMLS CUI [2])